Takeda and Koneksa Health Announce Strategic Collaboration to Use Digital Health Tools in Clinical Trials

CAMBRIDGE, Mass. & NEW YORK–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TSE:
4502) (“Takeda”) and Koneksa
Health, Inc. (“Koneksa”), an early stage company focused on the
integration of real world data into clinical research, today announced
an ongoing strategic collaboration to utilize new digital health tools
in clinical trials.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161107005011/en/

Using Koneksa’s leading technology data platform, Takeda is integrating
biosensor and wearable technology in several of its early stage clinical
studies. Koneksa’s technology enables the remote collection of data
measures that were previously difficult to obtain, such as patients’
continuous vital signs, activity levels and sleep metrics. These initial
clinical studies will also facilitate a performance qualification of
digital health tools relative to traditional in-clinic, gold-standard
assessments.

Takeda’s goal in pursuing this technology is to empower the development
of “digital biomarkers” that may improve decision-making and,
eventually, establish novel endpoints that will advance the assessment
of patients’ functional status in their natural settings.

“Working with Koneksa enables us to take advantage of technologies and
expertise that provide access to novel data streams and make our
clinical trials more patient-centric. Koneksa’s end-to-end solution
allows us to collect this data in our studies using Koneksa’s sensors
and devices,” said Elena Izmailova, PhD, Senior Director, Novel Data
Streams and Devices, at Takeda. “Takeda’s commitment to digital health
involves working with an ecosystem of external partners that, like
Koneksa, have a focus on both rigor and innovation.”

“Takeda has an exciting early pipeline of programs as well as a deep
commitment to ensuring that its therapies have the most meaningful
impact to patients, » said Chris Benko, Chief Executive Officer of
Koneksa. “This partnership provides Koneksa the opportunity to support
the development of exciting medicines while broadening our bench of
clinically validated sensor and device integrations.”

Wearable technology and remote, electronic patient data capture are
valuable tools for fortifying research with a sound foundational
framework. The study of disease progression or treatment effects, along
with the safety profile of new drugs, necessitates new forms of data
collection beyond the traditional patient-investigator rapport.
Koneksa’s method of data integration is designed to enhance the ability
to capture patients’ symptoms, interactions and day-to-day activities.

About Koneksa

Koneksa Health is a private technology company focused on the
incorporation of real-world data into clinical research. Koneksa works
primarily with data gathered through mobile, wearable and other digital
technologies. Koneksa is committed to transforming the way health is
measured by leveraging emergent technology in order to break data
collection out of the four walls of the clinic while improving the
quality of patient care and health outcomes data.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its R&D efforts on oncology,
gastroenterology and central nervous system therapeutic areas plus
vaccines. Takeda conducts R&D both internally and with partners to stay
at the leading edge of innovation. New innovative products, especially
in oncology and gastroenterology, as well as our presence in Emerging
Markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005011/en/